COMMUNIQUÉS West-GlobeNewswire

AC Immune to Regain Global Rights to Crenezumab and Semorinemab
22/01/2024
AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company’s strategy is focused on advancing the Phase 2 development of its three active immunotherapies Active immunotherapy now considered to be the [...]
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
22/01/2024
ZUG, Switzerland, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, [...]
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
22/01/2024
The pivotal Phase 3 trial with BNT323/DB-1303 follows positive Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced solid tumors with early signs of [...]
Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024
22/01/2024
ZUG, Switzerland, and BOSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or “the Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, [...]
Bionomics Provides a Review of 2023 and of 2024 Plans
22/01/2024
Positive Phase 2b data announced for BNC210 on reduction of total symptom severity and multiple symptom clusters in post-traumatic stress disorder (PTSD), with a discussion with the U.S. Food & Drug Administration ( [...]
Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)
22/01/2024
MELBOURNE, Australia, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s theranostic programs at the upcoming American [...]
Sosei Heptares Webinar Presentation for FY2023 Financial Results
22/01/2024
Tokyo, Japan and Cambridge, UK, 22 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the 12 months ended 31 [...]
Calibre Scientific Acquires RUWAG, a Swiss Provider of Diagnostics and Life Sciences Products and Services
22/01/2024
LOS ANGELES, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the acquisition of RUWAG Handels AG (“RUWAG” or the “Company”), a provider of diagnostics and life sciences products and services [...]
Calibre Scientific fait l’acquisition de RUWAG, un fournisseur suisse de produits et de services pour le diagnostic et les sciences de la vie
22/01/2024
LOS ANGELES, 22 janv. 2024 (GLOBE NEWSWIRE) -- Calibre Scientific a le plaisir d’annoncer l’acquisition de RUWAG Handels AG (« RUWAG » ou la « Société »), un fournisseur de produits et de services pour le diagnostic et [...]
ProteinLogic and Stellenbosch University receive $1.3 million grant to develop blood test to monitor response to TB antimicrobial chemotherapy
22/01/2024
ProteinLogic and Stellenbosch University receive $1.3 million grant to develop blood test to monitor response to TB antimicrobial chemotherapy ProteinLogic, Cambridge, UK and Stellenbosch University, South Africa [...]
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
22/01/2024
– Transaction aligns to Coherus’ strategic focus on oncology – – Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time – REDWOOD CITY, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“ [...]
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market
22/01/2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE CIMERLI ® *, a ranibizumab biosimilar, is interchangeable with LUCENTIS ® ** (ranibizumab-injection) for all approved indications [...]
InkSpace Imaging Announces Dr. E. Brian Welch, PhD, MBA as Vice President of Clinical Partnerships
20/01/2024
PLEASANTON, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- InkSpace Imaging today announced the appointment of Dr. E. Brian Welch, PhD, MBA, as Vice President of Clinical Partnerships. Dr. Welch has a proven track record of [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
19/01/2024
SAN CARLOS, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal [...]
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
19/01/2024
Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement FOSTER CITY, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (the “Company [...]
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/01/2024
MALVERN, Pa., Jan. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that [...]
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/01/2024
ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19/01/2024
NOVATO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare [...]
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
19/01/2024
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 [...]

Pages